Posted by Michael Wonder on 03 May 2023
Tenaya Therapeutics receives FDA fast track designation for TN-201
2 May 2023 - TN-201 being developed for the potential treatment of MYBPC3-associated HCM.
Tenaya Therapeutics today announced that the US FDA has granted fast track designation for its gene therapy product candidate, TN-201, being developed for the treatment of Myosin Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy.
